Abivax Shares Soar 15.4% at Close Amid Acquisition Rumors by Eli Lilly
The French biotech closed the session on December 22, 2025, at 115.40 euros, up sharply by 15.4% from the previous day. This increase occurred in the context of its inclusion in the Nasdaq Biotechnology Index and new speculations about a potential acquisition by the American laboratory Eli Lilly. The stock has shown an exceptional annual performance of 1,535%, confirming its status as the strongest rise in the SBF 120 in 2025.
Significant Closing Gain Amid Acquisition Talks
Abivax's stock closed on Monday, December 22, 2025, at 115.40 euros, marking a gain of 15.4% from the previous day's close of 100 euros. This rally is part of a long-term bullish dynamic, with a weekly increase of 6.65% and a three-month surge of 64.39%. The annual performance remains spectacular at 1,535%, placing the French biotech at the top of the SBF 120. According to La Lettre, a delegation from Eli Lilly visited the French Treasury Directorate at the beginning of December to explore a potential acquisition of the biotechnology company Abivax. Bercy, contacted by BFM Bourse, stated that it is closely monitoring the Abivax file, adding that checks are underway. Meanwhile, Abivax announced its inclusion in the Nasdaq Biotechnology Index effective December 22, 2025, enhancing its visibility among institutional investors. However, trading volumes remain modest, with only 0.5% of the capital traded on the day, reflecting a certain caution during this end-of-year period.
Financial Institutions Upgrade Abivax Price Targets
Several financial institutions have recently raised their price targets for Abivax. On the Nasdaq, Truist Securities initiated a buy recommendation on December 19 with a target of 140 euros, representing a potential upside of 21% from the current price. Leerink Partners also raised its target to 138 euros on December 17, while Piper Sandler & Co increased it to 142 euros on the same day, reflecting a consensus of optimism around the drug candidate obefazimod. Citizens maintained its outperform market recommendation with a target of 131 euros on December 16, and Wolfe Research set an ambitious target of 176 euros in early November. These successive upgrades reflect the growing confidence of analysts in the commercial potential of obefazimod, an oral treatment for ulcerative colitis, whose phase 3 results have been deemed promising. The company also has a comfortable cash position of 589.7 million euros as of September 30, 2025, ensuring financial autonomy until the fourth quarter of 2027. Abivax estimates that treatments for chronic inflammatory bowel diseases could represent a potential global market of 30 billion dollars by 2030.
Strong Performance Above Moving Averages
At 115.40 euros, the Abivax stock is trading well above its 50-day moving average of 93.90 euros, confirming a mid-term bullish trend. The gap with the 200-day moving average, positioned at 45.73 euros, illustrates the magnitude of the revaluation that occurred in 2025. The price is in the upper part of its Bollinger Bands, ranging between 89.67 euros and 117.70 euros, indicating the intensity of the movement without yet reaching the immediate resistance threshold of 115.80 euros. The RSI is at 45, in a neutral zone, leaving room before reaching an overbought level. However, the MACD indicator shows a bearish configuration with a MACD line at 1.11, below its signal line at 2.59, suggesting a short-term momentum fatigue. The monthly volatility, measured at 21.15%, remains high, reflecting the intensity of fluctuations linked to recent catalysts. With a beta of 0.10, the stock demonstrates an almost total decorrelation with the movements of the CAC 40, allowing for independent evolution regardless of the general trend of the Paris market. The support threshold at 89.40 euros is a level of vigilance in case of a turnaround.
